{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:50:49Z","timestamp":1786960249942,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572649"],"award-info":[{"award-number":["81572649"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702696"],"award-info":[{"award-number":["81702696"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2020A1515010176"],"award-info":[{"award-number":["2020A1515010176"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018a030313572"],"award-info":[{"award-number":["2018a030313572"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dean's Fund of Nanfang Hospital, Southern Medical University","award":["2019C019"],"award-info":[{"award-number":["2019C019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although the National Comprehensive Cancer Network (NCCN) Guidelines recommend CCRT+AC and IC\u2009+\u2009CCRT as level 2A evidence for treatment of the locoregionally advanced NPC (II-IVa), IC\u2009+\u2009CCRT+AC could also be an alternative but it is seldom used because of the low completion rates. This article aimed to compare the effectiveness of the three radiotherapy regimens using a large-scale retrospective study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective single center analysis enrolled 1812 diagnosed NPC patients at Nanfang Hospital from January 2005 to December 2015 and only 729 patients met the inclusion criteria and were analyzed. Patients without distant metastasis, age of 18\u201370\u2009years, Karnofsky scores of at least 70,stage III-IVb, and adequate adequate bone marrow, liver and renal function. Were enrolled. Adverse events and other categorical variables were compared by Pearson chi-square test or Fishier exact test. Time-to-event data were described with the Kaplan-Meier curves, time-to-event intervals compared with the log-rank test. We did multivariable analyses with the Cox proportional hazards model to test the independent signifi cance of diff erent factors. Cox proportional hazards model was used to estimate the \u03b2 regression coeffi cient, <jats:italic>p<\/jats:italic> value, and hazard ratio and its 95% CI for each of the selected risk predictors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up time was 47\u2009months. Kaplan-Meier analyses revealed no significant differences among three groups in 3-year failure-free survival (FFS, <jats:italic>P<\/jats:italic>\u2009=\u20090.225), 3-year overall survival (OS, <jats:italic>P<\/jats:italic>\u2009=\u20090.992), 3-year locoregional failure-free survival (LFFS, <jats:italic>P<\/jats:italic>\u2009=\u20090.549), and 3-year distant failure-free survival (DFFS, <jats:italic>P<\/jats:italic>\u2009=\u20090.174). Stratified survival analysis based on the risk scoring model revealed no differences in FFS, OS, LFFS, and DFFS between IC\u2009+\u2009CCRT and CCRT+AC groups for low-risk patients, however, the 3-year OS (88.3% vs. 77.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.049) and 3-year DFFS (84.0% vs.66.8%, <jats:italic>P<\/jats:italic>\u2009=\u20090.032) were respectively significantly better in IC\u2009+\u2009CCRT group compared with CCRT+AC group for high-risk patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with CCRT+AC, IC\u2009+\u2009CCRT lowers distant metastasis rate and improves OS among patients with locally advanced NPC in high risk group.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08381-8","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T09:03:11Z","timestamp":1625562191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model"],"prefix":"10.1186","volume":"21","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-6694","authenticated-orcid":false,"given":"Xiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"issue":"6","key":"8381_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"29","key":"8381_CR2","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","volume":"33","author":"AW Lee","year":"2015","unstructured":"Lee AW, Ma BB, Ng WT, Chan AT. Management of Nasopharyngeal Carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356\u201364. https:\/\/doi.org\/10.1200\/JCO.2015.60.9347.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8381_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","volume":"21","author":"JC Lin","year":"2003","unstructured":"Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21(4):631\u20137. https:\/\/doi.org\/10.1200\/JCO.2003.06.158.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8381_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310\u20137. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8381_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.radonc.2014.05.005","volume":"112","author":"F Wu","year":"2014","unstructured":"Wu F, Wang R, Lu H, Wei B, Feng G, Li G, et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective, multicentric clinical study. Radiother Oncol. 2014;112(1):106\u201311. https:\/\/doi.org\/10.1016\/j.radonc.2014.05.005.","journal-title":"Radiother Oncol"},{"issue":"2","key":"8381_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.18.1545.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8381_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/annonc\/mdr116","volume":"23","author":"G Fountzilas","year":"2012","unstructured":"Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic cooperative oncology group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23(2):427\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdr116.","journal-title":"Ann Oncol"},{"issue":"5","key":"8381_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","volume":"91","author":"T Tan","year":"2015","unstructured":"Tan T, Lim WT, Fong KW, Cheah SL, Soong YL, Ang MK, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91(5):952\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.002.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"8381_CR9","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.ejca.2015.05.025","volume":"51","author":"PY Huang","year":"2015","unstructured":"Huang PY, Zeng Q, Cao KJ, Guo X, Guo L, Mo HY, et al. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: a single-institution experience from an endemic area. Eur J Cancer. 2015;51(13):1760\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.025.","journal-title":"Eur J Cancer"},{"key":"8381_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","volume":"75","author":"SM Cao","year":"2017","unstructured":"Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14\u201323. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.039.","journal-title":"Eur J Cancer"},{"issue":"11","key":"8381_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li W-F, Chen N-Y, Zhang N, Hu G-Q, Xie F-Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(16)30410-7.","journal-title":"Lancet Oncol"},{"issue":"12","key":"8381_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1905287.","journal-title":"N Engl J Med"},{"issue":"27","key":"8381_CR13","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","volume":"23","author":"J Wee","year":"2005","unstructured":"Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American joint committee on Cancer\/international union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23(27):6730\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.16.790.","journal-title":"J Clin Oncol"},{"issue":"15","key":"8381_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/jnci\/djq258","volume":"102","author":"AWM Lee","year":"2010","unstructured":"Lee AWM, Tung SY, Chua DTT, Ngan RKC, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. JNCI J Natl Cancer Inst. 2010;102(15):1188\u201398. https:\/\/doi.org\/10.1093\/jnci\/djq258.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"8381_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oraloncology.2016.11.008","volume":"64","author":"YC Liu","year":"2017","unstructured":"Liu YC, Wang WY, Twu CW, Jiang RS, Liang KL, Wu CT, et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. Oral Oncol. 2017;64:15\u201321. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.11.008.","journal-title":"Oral Oncol"},{"issue":"5","key":"8381_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498\u2013505. https:\/\/doi.org\/10.1200\/JCO.2016.67.4119.","journal-title":"J Clin Oncol"},{"key":"8381_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/CMAR.S185932","volume":"11","author":"L Li","year":"2019","unstructured":"Li L, Liang W, Zhu JX, Dong CJ, Zou YM, Ye BC, et al. Evolutionary role of chemotherapy in advanced nasopharyngeal carcinoma: a literature-based network meta-analysis. Cancer Manag Res. 2019;11:501\u201312. https:\/\/doi.org\/10.2147\/CMAR.S185932.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"8381_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(15)70126-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8381_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","volume":"13","author":"L Chen","year":"2012","unstructured":"Chen L, Hu C-S, Chen X-Z, Hu G-Q, Cheng Z-B, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(11)70320-5.","journal-title":"Lancet Oncol"},{"issue":"13","key":"8381_CR20","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.2004.05.173","volume":"22","author":"DL Kwong","year":"2004","unstructured":"Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22(13):2643\u201353. https:\/\/doi.org\/10.1200\/JCO.2004.05.173.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8381_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.699579.","journal-title":"Circulation"},{"issue":"5 Pt A","key":"8381_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.hrthm.2020.01.006","volume":"17","author":"Y Okubo","year":"2020","unstructured":"Okubo Y, Nakano Y, Ochi H, Onohara Y, Tokuyama T, Motoda C, et al. Predicting atrial fibrillation using a combination of genetic risk score and clinical risk factors. Heart Rhythm. 2020;17(5 Pt A):699\u2013705.","journal-title":"Heart Rhythm"},{"issue":"6","key":"8381_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","volume":"12","author":"H-I Yang","year":"2011","unstructured":"Yang H-I, Yuen M-F, Chan HL-Y, Han K-H, Chen P-J, Kim D-Y, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(11)70077-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8381_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.tp.0000267916.36343.ca","volume":"84","author":"S Iacob","year":"2007","unstructured":"Iacob S, Cicinnati VR, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation. 2007;84(1):56\u201363. https:\/\/doi.org\/10.1097\/01.tp.0000267916.36343.ca.","journal-title":"Transplantation"},{"issue":"5","key":"8381_CR25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/ije\/dyaa089","volume":"49","author":"DH Sinn","year":"2020","unstructured":"Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, et al. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol. 2020;49(5):1562\u201371. https:\/\/doi.org\/10.1093\/ije\/dyaa089.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"8381_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10555-017-9693-x","volume":"36","author":"Y Nakanishi","year":"2017","unstructured":"Nakanishi Y, Wakisaka N, Kondo S, Endo K, Sugimoto H, Hatano M, et al. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev. 2017;36(3):435\u201347. https:\/\/doi.org\/10.1007\/s10555-017-9693-x.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"8381_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/1471-2407-13-226","volume":"13","author":"G Xiao","year":"2013","unstructured":"Xiao G, Cao Y, Qiu X, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer. 2013;13(1):226. https:\/\/doi.org\/10.1186\/1471-2407-13-226.","journal-title":"BMC Cancer"},{"issue":"5","key":"8381_CR28","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cam4.2083","volume":"8","author":"T Hu","year":"2019","unstructured":"Hu T, Lin CY, Xie SH, Chen GH, Lu YQ, Ling W, et al. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr virus: an analysis of a prospective study in southern China. Cancer Med. 2019;8(5):2561\u201371. https:\/\/doi.org\/10.1002\/cam4.2083.","journal-title":"Cancer Med"},{"issue":"1","key":"8381_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1748-717X-8-265","volume":"8","author":"X Sun","year":"2013","unstructured":"Sun X, Zeng L, Chen C, Huang Y, Han F, Xiao W, et al. Comparing treatment outcomes of different chemotherapy sequences during intensity modulated radiotherapy for advanced N-stage nasopharyngeal carcinoma patients. Radiat Oncol. 2013;8(1):265. https:\/\/doi.org\/10.1186\/1748-717X-8-265.","journal-title":"Radiat Oncol"},{"issue":"1","key":"8381_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2014.01.052","volume":"89","author":"CW Twu","year":"2014","unstructured":"Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.052.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"8381_CR31","doi-asserted-by":"publisher","first-page":"41449","DOI":"10.1038\/srep41449","volume":"7","author":"ZG Liang","year":"2017","unstructured":"Liang ZG, Chen XQ, Lin GX, Yu BB, Chen KH, Zhong QL, et al. Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma. Sci Rep. 2017;7(1):41449. https:\/\/doi.org\/10.1038\/srep41449.","journal-title":"Sci Rep"},{"issue":"4","key":"8381_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/annonc\/mdq426","volume":"22","author":"A Argiris","year":"2011","unstructured":"Argiris A, Karamouzis MV. Empowering induction therapy for locally advanced head and neck cancer. Ann Oncol. 2011;22(4):773\u201381. https:\/\/doi.org\/10.1093\/annonc\/mdq426.","journal-title":"Ann Oncol"},{"issue":"22","key":"8381_CR33","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1200\/JCO.2004.10.074","volume":"22","author":"JA Langendijk","year":"2004","unstructured":"Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22(22):4604\u201312. https:\/\/doi.org\/10.1200\/JCO.2004.10.074.","journal-title":"J Clin Oncol"},{"issue":"9","key":"8381_CR34","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.ejca.2013.03.003","volume":"49","author":"WX Xia","year":"2013","unstructured":"Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Eur J Cancer. 2013;49(9):2152\u201360. https:\/\/doi.org\/10.1016\/j.ejca.2013.03.003.","journal-title":"Eur J Cancer"},{"issue":"3","key":"8381_CR35","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/j.ijrobp.2011.06.1967","volume":"82","author":"GQ Zhou","year":"2012","unstructured":"Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys. 2012;82(3):e359\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.06.1967.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08381-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T09:11:16Z","timestamp":1625562676000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08381-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8381"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08381-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study is a retrospective cohort study. However, due to the fact that a small number of patients in our follow-up came from various provinces in China, were far away or had died, and could not obtain the patients to sign the relevant consent, we consulted the ethics committee of our hospital, and the ethics will inform us, because there is no privacy and tissue samples or blood samples in this study, we can obtain the oral consent of the patient\u2019s family members by phone and then query the relevant information in the case system for retrospective research. Ethical documents was approved by the Medical Ethics Committee of Nanfang Hospital (NFEC-2017-165).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"639"}}